Maximal Medical Treatment of Intracerebral Haemorrhage Pilot Trial - MAX-ICH Pilot Trial
Key facts
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 7 Aug 2025
- Expected to end
- 30 Nov 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- MAX-ICH care bundle
- Standard of care
- Record updated
- 2 July 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Symptomatic imaging proven diagnosis of non-traumatic ICH
- Vascular imaging (MR-/CT-angiogram or DSA) on admission to rule out high suspicion of macrovascular bleeding source
- Enrolment no later than 6 hours of symptom onset
- Age >18 years, no upper age limit
- Informed consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent
Who cannot take part
- Palliative care/comfort therapy decision in the emergency department
- Active participation in another drug or devices trial concurrently
- ICH due to trauma (major head trauma <24 hours of symptom onset causing loss of consciousness and thought to be sufficient to have caused the intracerebral bleeding)
- High suspicion of ICH due to arteriovenous malformation (AVM), aneurysm or sinus-venous-thrombosis confirmed by neuroimaging, brain tumor, vasculitis, RCVS/PRES or system disease (liver disease, inherit coagulopathy)
- Contraindications against Clevidipine (allergy to soja, lipid metabolism defect or known severe aortic stenosis)
- Severe ICH (haematoma volume >60ml or GCS <8)
- Haematoma evacuation or decompressive craniectomy within 72 hours planned or highly likely (isolated EVD is not an exclusion criterion)
- Severe pre-morbid disability [modified Rankin scale (mRS) is ≥4]
- Contraindication against the use of tranexamic acid
- Female patient that are either pregnant or breastfeeding
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The MAX-ICH pilot trial is a phase-II study aimed at assessing the feasibility and safety of a comprehensive care bundle for patients with intracerebral hemorrhage (ICH). This "maximal medical treatment" approach combines advanced interventions like intensive blood pressure control, rapid anticoagulation reversal, and tranexamic acid administration to potentially improve outcomes. The primary objective is to evaluate recruitment feasibility over 12 months, while secondary objectives include protocol adherence, safety monitoring, and the exploration of clinical outcomes. The study focuses on the critical first 72 hours of care to determine if this approach can be effectively implemented in clinical practice.
The 2 groups in the trial
- Control arm (usual care)Other group
Control group is treated according to local standard of care
Treatment: Standard of care
- Experimental arm (MAX-ICH care bundle)Treatment being tested
Experimental group is treated according MAX-ICH care bundle
Treatment: MAX-ICH care bundle
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06648369, who can take part
- Record updated
- 2 July 2026